Edwards Lifesciences (EW) Stock Price, News & Analysis

Company Overview

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams. The company also produces hemodynamic monitoring platforms and consumables intended for perioperative and intensive care settings to support patient management during high-acuity procedures. Customers include hospitals and health systems across multiple geographies, and Edwards distributes its products globally in markets such as North America, Europe and the Asia-Pacific region.

Edwards Lifesciences has a long-standing emphasis on research, clinical evidence and product innovation, pursuing clinical trials and regulatory approvals to expand indications for existing therapies and to develop new treatments for other forms of structural heart disease. Its business model combines manufacturing, direct sales and partnerships to support training, clinical adoption and post-market surveillance. The company’s strategic focus remains on advancing less-invasive cardiac therapies and improving outcomes for patients with valvular and critical cardiovascular conditions.

Key Stats

• Today's Range: $81.32 to $83.58
• 50-Day Range: $77.85 to $87.27
• 52-Week Range: $72.30 to $87.89
• Volume: 689,542 shs
• Average Volume: 4.78 million shs
• Market Capitalization: $47.96 billion
• P/E Ratio: 44.23
• Dividend Yield: N/A
• Price Target: $95.65
• Consensus Rating: Moderate Buy

Edwards Lifesciences Stock Analysis - MarketRank™

Edwards Lifesciences scored higher than 85% of companies evaluated by MarketBeat, and ranked 93rd out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Edwards Lifesciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 3 strong buy ratings, 16 buy ratings, 9 hold ratings, and no sell ratings.

Upside Potential

Edwards Lifesciences has a consensus price target of $95.65, representing about 16.7% upside from its current price of $81.97.

Amount of Analyst Coverage

Edwards Lifesciences has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 11.67%

Earnings Growth

Earnings for Edwards Lifesciences are expected to grow by 11.67% in the coming year, from $3.00 to $3.35 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Edwards Lifesciences is 43.84, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.28.

Price to Earnings Ratio vs. Sector

The P/E ratio of Edwards Lifesciences is 43.84, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.02.

Price to Earnings Growth Ratio

Edwards Lifesciences has a PEG Ratio of 2.09. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Edwards Lifesciences has a P/B Ratio of 4.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.62% of the float of Edwards Lifesciences has been sold short.

Short Interest Ratio / Days to Cover

Edwards Lifesciences has a short interest ratio ("days to cover") of 1.97, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Edwards Lifesciences has recently decreased by 6.42%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Edwards Lifesciences does not currently pay a dividend.

Dividend Growth

Edwards Lifesciences does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.95

News Sentiment

Edwards Lifesciences has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 22 news articles for Edwards Lifesciences this week, compared to 8 articles on an average week.

Search Interest

13 people have searched for EW on MarketBeat in the last 30 days. This is an increase of 1,200% compared to the previous 30 days.

MarketBeat Follows

6 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,288,799.00 in company stock.

Percentage Held by Insiders

0.31% of the stock of Edwards Lifesciences is held by insiders.

Percentage Held by Institutions

79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EW Stock Analysis - Frequently Asked Questions

How have EW shares performed this year?

Edwards Lifesciences' stock was trading at $85.26 at the beginning of 2026. Since then, EW stock has decreased by 3.9% and is now trading at $81.9650.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Corporation (NYSE:EW) issued its quarterly earnings results on Thursday, April, 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. The firm's quarterly revenue was up 16.7% on a year-over-year basis.
Read the conference call transcript.

When did Edwards Lifesciences' stock split?

Shares of Edwards Lifesciences split on Friday, May 29th 2020.The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were distributed to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Does Edwards Lifesciences have any subsidiaries?

Edwards Lifesciences subsidiaries include these companies: CAS Medical Systems, Harpoon Medical, Valtech Cardio, CardiAQ Valve Technologies, BMEYE, Embrella Cardiovascular, Myocor, and more.

Who are Edwards Lifesciences' major shareholders?

Top institutional investors of Edwards Lifesciences include Bank of New York Mellon Corp (2.90%), Allspring Global Investments Holdings LLC (0.36%), Sumitomo Mitsui Trust Group Inc. (0.22%) and Assenagon Asset Management S.A. (0.22%). Insiders that own company stock include Larry L Wood, Jean-Luc M Lemercier, Kieran Gallahue, Steven R Loranger, Bernard J Zovighian, Scott B Ullem, Catherine M Szyman, Daniel J Lippis, Daveen Chopra, Heisz Leslie Stone, Donald E Bobo Jr, Robert WA Sellers, Wayne Markowitz and Michael A Mussallem.
View institutional ownership trends.

How do I buy shares of Edwards Lifesciences?

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Edwards Lifesciences investors own include Comcast (CMCSA), Chevron (CVX), Bristol Myers Squibb (BMY), Charles Schwab (SCHW), McKesson (MCK), Yum! Brands (YUM) and Toronto Dominion Bank (TD).

Company Calendar

• Last Earnings: 4/23/2026
• Today: 5/06/2026
• Bank of America Global Healthcare Conference 2026: 5/12/2026
• Next Earnings (Estimated): 7/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NYSE:EW
• CIK: 1099800
• Web: www.edwards.com
• Phone: (949) 250-2500
• Fax: 949-250-2525
• Employees: 16,000
• Year Founded: 1958

Price Target and Rating

• Average Price Target for Edwards Lifesciences: $95.65
• High Price Target: $110.00
• Low Price Target: $81.00
• Potential Upside/Downside: +14.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.79
• Research Coverage: 28 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.88
• Trailing P/E Ratio: 44.40
• Forward P/E Ratio: 27.82
• P/E Growth: 2.09
• Net Income: $1.07 billion
• Net Margins: 17.39%
• Pretax Margin: 20.59%
• Return on Equity: 15.17%
• Return on Assets: 11.68%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 3.72
• Quick Ratio: 3.09

Sales & Book Value

• Annual Sales: $6.07 billion
• Price / Sales: 7.93
• Cash Flow: $2.86 per share
• Price / Cash Flow: 29.22
• Book Value: $17.81 per share
• Price / Book: 4.69

Miscellaneous

• Outstanding Shares: 576,540,000
• Free Float: 574,755,000
• Market Cap: $48.12 billion
• Optionable: Optionable
• Beta: 0.87